Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | CSF1R | P07333 | 1/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.57 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.57 |
| ▸ | CDK7 | P50613 | 1/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179920 | 0.83 | KDR (1.00) | KDRABL1LCKCSF1RPDGFRB | |
| SCHEMBL6330404 | 0.80 | KDR (1.00) | KDR | |
| SCHEMBL6180701 | 0.79 | KDR (0.74) | KDRABL1LCKCSF1RPDGFRB | |
| SCHEMBL6178940 | 0.77 | KDR (0.70) | KDRABL1LCKCSF1RPDGFRB | |
| SCHEMBL7237283 | 0.77 | KDR (1.00) | KDRABL1LCKCSF1RPDGFRB | |
| SCHEMBL7227864 | 0.77 | KDR (1.00) | KDRABL1LCKCSF1RPDGFRB | |
| SCHEMBL13701560 | 0.77 | KDR (0.81) | KDR | |
| SCHEMBL3651635 | 0.76 | KDR (1.00) | KDR | |
| SCHEMBL6330184 | 0.75 | KDR (1.00) | KDRABL1PDGFRB | |
| SCHEMBL7228041 | 0.74 | KDR (1.00) | KDRABL1LCKCSF1RPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115597-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| EP-1341540-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
| WO-2002045652-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885ABL1 77/4885LCK 16/4885 |
| US-20040063720-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885ABL1 77/4885LCK 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.